Andrei‐Mircea Catarig

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

Matthew Capehorn, Andrei‐Mircea Catarig, Julie Kjærulff Furberg et al. · Diabetes & Metabolism · 2019 · 376 citations

Diabetes Management, Diabetes, Pharmacology +7

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Ildiko Lingvay, Andrei‐Mircea Catarig, Juan P. Frías et al. · The Lancet Diabetes & Endocrinology · 2019 · 265 citations · Full text

Diabetes Management, Sustain 8, Medicine +6

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

Rory J. McCrimmon, Andrei‐Mircea Catarig, Juan P. Frías et al. · Diabetologia · 2020 · 135 citations · Full text

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

Marc P. Bonaca, Andrei‐Mircea Catarig, Kim Christian Houlind et al. · The Lancet · 2025 · 76 citations

Metabolic Syndrome, Diabetes Management, Physical Activity +10

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study

Neda Rajamand Ekberg, Ulrik Bodholdt, Andrei‐Mircea Catarig et al. · Primary care diabetes · 2021 · 56 citations · Full text